Sutro Biopharma (STRO) Profit After Tax (2017 - 2025)

Sutro Biopharma has disclosed Profit After Tax across 9 years of filings, most recently posting -$46.8 million for Q4 2025.

• Profit After Tax for Q4 2025 came in at -$46.8 million, up 35.45% year-over-year; the trailing twelve-month figure through Dec 2025 was -$191.1 million (up 15.99% YoY), and the FY2025 annual result was -$191.1 million, up 15.99% from the prior year.
• Profit After Tax came in at -$46.8 million for Q4 2025 at Sutro Biopharma, up from -$56.9 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $31.1 million in Q4 2023 to a low of -$76.0 million in Q1 2025.
• The 5-year median for Profit After Tax is -$38.8 million (2022), against an average of -$37.5 million.
• Across the five-year window, Profit After Tax jumped 189.8% in 2023 and plunged 333.2% in 2024, its largest moves.
• Sutro Biopharma's Profit After Tax stood at -$38.1 million in 2021, then gained by 9.26% to -$34.6 million in 2022, then surged by 189.8% to $31.1 million in 2023, then slumped by 333.2% to -$72.4 million in 2024, then soared by 35.45% to -$46.8 million in 2025.
• The last three Profit After Tax figures came in at -$46.8 million (Q4 2025), -$56.9 million (Q3 2025), and -$11.5 million (Q2 2025), per Business Quant data.